- Home
- ITRM
as 04-23-2025 4:00pm EST
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
| Founded: | 2015 | Country: | Ireland |
| Employees: | N/A | City: | DUBLIN 1 |
| Market Cap: | 37.7M | IPO Year: | 2018 |
| Target Price: | $5.00 | AVG Volume (30 days): | 364.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.26 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.81 - $3.02 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 150.10% |
Latest Iterum Therapeutics plc News
ITRM Breaking Stock News: Dive into ITRM Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics
GuruFocus.com
3 months ago
Iterum Therapeutics PLC (ITRM) Q4 2024 Earnings Call Highlights: Navigating Financial ...
Thomson Reuters StreetEvents
3 months ago
Q4 2024 Iterum Therapeutics PLC Earnings Call
GlobeNewswire
3 months ago
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
3 months ago
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
MT Newswires
5 months ago
Iterum Therapeutics Shares Rise After Regaining Compliance With Nasdaq's Listing Rules
GlobeNewswire
5 months ago
Iterum Therapeutics Regains Full Nasdaq Compliance
GuruFocus.com
5 months ago
Iterum Therapeutics PLC (ITRM) Q3 2024 Earnings Call Highlights: Strategic Moves Amid Financial ...
Compare ITRM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ITRM Iterum Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.